Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New nasal swab test could spot hidden viruses in seniors

NCT ID NCT07601412

Diagnosis Sponsor: Hospices Civils de Lyon Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing whether measuring a natural immune marker called IFN-I in nasal swabs can help detect respiratory viral infections in older adults. Current PCR tests only look for a few viruses and can miss others or show old infections. The goal is to improve diagnosis, especially in geriatric wards, to better manage outbreaks and care. Researchers will compare the IFN-I score with standard PCR results in over 1,100 participants.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
IFN-I score measurement from nasal swabs
What this could lead to
If successful, this could lead to a faster, more accurate diagnostic test for respiratory viral infections in elderly patients, helping to guide isolation and treatment decisions.
What could go wrong
This is an early-stage diagnostic study, not a treatment trial. The IFN-I response may be weaker in older adults, and the test may not reliably distinguish active from past infections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,140 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2024

Expected to finish

Jul 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This study focuses on nasopharyngeal swabs taken as part of clinical care to screen for respiratory viruses in patients admitted to geriatric wards, or as part of the REFIPA protocol (NCT07239830) in older, asymptomatic, non-hospitalised participants. For hospitalised patients, first-line microbiological tests (RSV, SARS-CoV-2 and influenza) as well as viral culture are carried out as part of routine diagnostic testing. For participants in the REFIPA protocol (NCT07239830), samples were collected as part of this study. Thus, all samples are collected as part of standard care in hospitalised patients in geriatric wards presenting with signs of respiratory distress, or as part of the REFIPA protocol in asymptomatic, non-hospitalised elderly participants. The IFN-I score and the results of second-line tests will not be disclosed to the patient's doctor. They will therefore have no impact on the patient's treatment.

Ages

60 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients admitted to a geriatric ward or participants diagnosed with a PCR-positive infection based on a swab sample taken as part of the REFIPA study (NCT07239830). Nasopharyngeal swab taken for viral detection, where the viral test was carried out as part of standard clinical care (minimum 500 µL required) Exclusion Criteria: * The patient's objection to the use of their data in this study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Respiratory viral infection are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

disease viral respiratory tract infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Respiratory viral infection

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hôpital Lyon Sud

    RECRUITING

    Lyon, 69310, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.